Reducing level of daily alcohol consumption or sustained quitting of alcohol linked to lower risk for alcohol-related and all cancers
THURSDAY, Aug. 25, 2022 (HealthDay News) — Adults who increase their alcohol consumption may have a higher risk for alcohol-related cancers and all cancers versus adults who had sustained quitting or reduced levels of drinking, according to a study published online Aug. 24 in JAMA Network Open.
Jung Eun Yoo, M.D., Ph.D., from Seoul National University Hospital in South Korea, and colleagues used data from the Korean National Health Insurance Service (4.5 million participants) to examine the association between the reduction, cessation, or increase of alcohol consumption and the development of alcohol-related cancers and all cancers.
The researchers found that compared with the sustainer groups at each drinking level, the increaser groups had a higher risk for alcohol-related cancers and all cancers. Those who changed from nondrinking to mild, moderate, or heavy drinking levels had a higher risk than those who did not drink. A lower risk for alcohol-related cancer was seen among those with mild drinking levels who quit drinking versus those who sustained their drinking levels. Reducing heavy drinking levels to moderate or mild levels was associated with decreased cancer risk versus sustained heavy drinking. Compared with individuals who sustained their drinking levels, those with moderate or heavy drinking levels who quit drinking had a higher incidence of all cancer; however, this increase in risk disappeared when quitting was sustained.
“Findings of this study suggest that drinking cessation and reduction should be reinforced for the prevention of cancer,” the authors write.
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Couples" Coping Skills Help Reduce Depression in GI Cancer Survivors
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy